12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Adult stem cells: Phase II start

Mesoblast said in its earnings for 1H13 ended Dec. 31, 2012, that in May it plans to begin a double-blind, placebo-controlled, dose-escalation Phase II trial comparing single IV infusions of 1 and 2 million MPCs/kg over 3 months in 48 patients. Mesoblast...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >